The demonstrated benefits of TKIs as part of non-transplant therapy for FLT3-mutated AML [127,128,129] generated interest in their use as pre-emptive maintenance therapies after allogeneic HCT. This evidence concerns the gene FLT3 and acute myeloid leukemia.